Related Experiment Videos
[Clinical pharmacology of the new antiarrhythmia agents]
1Departamento de Farmacología, Faculdad de Medicina, Universidad Complutense-28040 Madrid.
Insights
New antiarrhythmic drugs (ADs) are being developed to treat cardiac arrhythmias, focusing on class III ADs and genetic targets for improved efficacy and safety.
Area of Science:
- Cardiovascular Pharmacology
- Cardiac Electrophysiology
- Molecular Genetics
Context:
- Cardiac arrhythmias require treatment for symptom relief and mortality reduction.
- Class I antiarrhythmic drugs (ADs) show increased mortality in coronary artery disease patients.
- Interest is shifting towards class III ADs, especially those effective at fast heart rates or selective for atrial tissue.
Purpose:
- To explore new perspectives in developing novel antiarrhythmic drugs (ADs).
- To identify new therapeutic targets for antiarrhythmic drug development.
- To design safer and more effective antiarrhythmic therapies.
Summary:
- Cardiac arrhythmias are treated with antiarrhythmic drugs (ADs), with a shift from Class I to Class III agents.
- Genetic variations and altered cardiac electrophysiology in heart disease present new targets for AD development.
- Future ADs may target the arrhythmogenic substrate, offering improved efficacy and reduced complications.
Impact:
- Advances in molecular genetics and electrophysiology enable the identification of novel drug targets.
- Development of new ADs with enhanced effectiveness and reduced side effect profiles.
- Potential for improved patient outcomes and decreased arrhythmic death rates.
Abstract:
Antiarrhythmic drugs (ADs) are the mainstay in the treatment of cardiac arrhythmias. Arrhythmias merit treatment for the relief of symptoms and for the prolongation of survival for decreasing arrhythmic deaths. Since class I ADs can increase arrhythmia mortality in patients with coronary artery disease the interest has shifted to class III ADs, particularly those with greater effect at fast heart rates or with greater selectivity for atrial tissue. The recognition that some cardiac arrhythmias can be attributed to variable expression of specific genes or variability in the function of their protein products offers new perspectives for developing new ADs Moreover, the finding that heart disease alters electrophysiological properties of cardiac tissue suggests that we must target the arrhythmogenic substrate rather than its final electrical product. Advances in molecular genetics and electrophysiology will provide an opportunity to identify new targets and to design new ADs that are more effective and with lower risk of complications than those presently prescribed.